Photo from wikipedia
With the evolution of peptide receptor radionuclide therapy (PRRT) in the mainstream management of metastatic/advanced neuroendocrine tumors (NETs), one area of particular interest is to define its place in the… Click to show full abstract
With the evolution of peptide receptor radionuclide therapy (PRRT) in the mainstream management of metastatic/advanced neuroendocrine tumors (NETs), one area of particular interest is to define its place in the neoadjuvant setting of pancreatic NET and develop an effective and optimal clinical protocol for treatment, monitoring, and evaluation for surgical feasibility. Hence, it is worthwhile for the nuclear medicine fraternity to be aware of the nuances and the determinants so as to be able to deliver the most effective treatment to maximize the possibility of surgical resection.
Journal Title: Nuclear Medicine Communications
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!